Zachariah Serber - 24 Jan 2022 Form 4 Insider Report for Zymergen Inc. (ZY)

Role
Chief Science Officer, Director
Signature
/s/ Mina Kim, attorney-in-fact
Issuer symbol
ZY
Transactions as of
24 Jan 2022
Net transactions value
-$103,446
Form type
4
Filing time
26 Jan 2022, 16:54:23 UTC
Next filing
02 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZY Common Stock Sale $103,446 -21,730 -0.9% $4.76 2,391,220 24 Jan 2022 Direct F1, F2
holding ZY Common Stock 40,000 24 Jan 2022 See Footnote F3
holding ZY Common Stock 40,000 24 Jan 2022 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2021 that provides for the sale of up to 250,000 shares over the next ten (10) months.
F2 Transaction executed in multiple trades at prices ranging from $4.50 to $5.05 per share, inclusive. The price reported in column 4 above reflects the weighted average sale price per share. The Reporting Person hereby undertakes to provide the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Held by the Rorik Serber 2021 Irrevocable Trust.
F4 Held by spouse as custodian for children under the California Uniform Transfer to Minors Act.